Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

Oral TDF/FTC is approved for daily PrEP by an increasing number of countries worldwide and is recommended by WHO as an additional prevention tool. Intermittent on-demand, or sex-driven, PrEP has been assessed in a limited number of studies and, although recommended by the European AIDS Clinical Society and French, UK and Canadian guidelines for men who have sex with men (MSM), it is not yet widely accepted as an alternative for daily PrEP. This session reviews the current evidence for on-demand PrEP, from animal models to pharmacokinetics (PK), and summarizes recent data among MSM; while also addressing current knowledge gaps to encourage future research, particularly among heterosexual men and women. The content is targeted at healthcare providers, community advocates, regulators, pharmacologists, researchers in prevention, private and public agencies, and individuals using PrEP and gives participants a better understanding of on-demand PrEP as a viable alternative to daily PrEP.

16:30
MOSY0801
Introduction
Sheena McCormack, University College London (UCL), United Kingdom
16:35
MOSY0802
Input from animal models
Walid Heneine, Centers for Disease Control (CDC), United States
16:50
MOSY0803
Does pharmacology support on demand PrEP?
Angela Kashuba, University of North Carolina, United States
Slides
17:05
MOSY0804
Review of clinical studies of intermittent PrEP
Robert Grant, Gladstone Institutes/UCSF, United States
Slides
17:20
MOSY0805
Acceptability and adherence to intermittent sex-driven PrEP
Timothy Holtz, Centers for Disease Control and Prevention (CDC), India
Slides
17:35
MOSY0806
Questions and answers
Sheena McCormack, University College London (UCL), United Kingdom
Slides
17:55
MOSY0807
Closing remarks